Eliana Merle
Stock Analyst at UBS
(2.23)
# 2,685
Out of 4,876 analysts
84
Total ratings
40.32%
Success rate
-1.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVAC CureVac | Downgrades: Neutral | $12 → $5.5 | $5.44 | +1.10% | 3 | Jun 26, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $16 → $8 | $8.11 | -1.36% | 3 | May 22, 2025 | |
| ARVN Arvinas | Maintains: Buy | $74 → $21 | $7.36 | +185.33% | 4 | May 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $72 → $70 | $43.66 | +60.33% | 3 | May 13, 2025 | |
| MRNA Moderna | Maintains: Buy | $78 → $70 | $27.59 | +153.72% | 7 | May 2, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $441 → $458 | $302.64 | +51.33% | 4 | May 2, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $65 → $72 | $43.20 | +66.69% | 3 | Apr 30, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Overweight | $44 | $17.30 | +154.41% | 8 | Apr 29, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $109 → $113 | $54.99 | +105.49% | 2 | Feb 20, 2025 | |
| ETNB 89bio | Maintains: Buy | $25 → $38 | $9.85 | +285.98% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $53.36 | +104.27% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.16 | +89.66% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $36.80 | +92.93% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $196 | $171.46 | +14.31% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $9.58 | +192.28% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $7.62 | +57.48% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $3.04 | -1.32% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $3.87 | +571.83% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $22.15 | +48.98% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $106.47 | +23.04% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $326.09 | -11.68% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $3.72 | +34.41% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $3.75 | +380.00% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $13.94 | +201.29% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $1.23 | +550.41% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.52 | +387.26% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.22 | +471.78% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.73 | +179.23% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $28.00 | +378.66% | 3 | Aug 19, 2020 |
CureVac
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $5.44
Upside: +1.10%
RAPT Therapeutics
May 22, 2025
Maintains: Neutral
Price Target: $16 → $8
Current: $8.11
Upside: -1.36%
Arvinas
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $7.36
Upside: +185.33%
Kymera Therapeutics
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $43.66
Upside: +60.33%
Moderna
May 2, 2025
Maintains: Buy
Price Target: $78 → $70
Current: $27.59
Upside: +153.72%
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $441 → $458
Current: $302.64
Upside: +51.33%
BridgeBio Pharma
Apr 30, 2025
Maintains: Buy
Price Target: $65 → $72
Current: $43.20
Upside: +66.69%
Apellis Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $17.30
Upside: +154.41%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Buy
Price Target: $109 → $113
Current: $54.99
Upside: +105.49%
89bio
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $9.85
Upside: +285.98%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $53.36
Upside: +104.27%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.16
Upside: +89.66%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $36.80
Upside: +92.93%
Jan 7, 2025
Initiates: Buy
Price Target: $196
Current: $171.46
Upside: +14.31%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $9.58
Upside: +192.28%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $7.62
Upside: +57.48%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $3.04
Upside: -1.32%
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $3.87
Upside: +571.83%
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $22.15
Upside: +48.98%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $106.47
Upside: +23.04%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $326.09
Upside: -11.68%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $3.72
Upside: +34.41%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $3.75
Upside: +380.00%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $13.94
Upside: +201.29%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $1.23
Upside: +550.41%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $4.52
Upside: +387.26%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.22
Upside: +471.78%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $5.73
Upside: +179.23%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $28.00
Upside: +378.66%